- Home
- OPRA vs IBRX Comparison
OPRA vs IBRX Comparison
Compare OPRA & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRA
- IBRX
- Stock Information
- Founded
- OPRA 1996
- IBRX 2014
- Country
- OPRA Norway
- IBRX United States
- Employees
- OPRA N/A
- IBRX N/A
- Industry
- OPRA Computer Software: Prepackaged Software
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPRA Technology
- IBRX Health Care
- Exchange
- OPRA Nasdaq
- IBRX Nasdaq
- Market Cap
- OPRA 1.6B
- IBRX 1.9B
- IPO Year
- OPRA 2018
- IBRX N/A
- Fundamental
- Price
- OPRA $19.59
- IBRX $3.42
- Analyst Decision
- OPRA Strong Buy
- IBRX Strong Buy
- Analyst Count
- OPRA 5
- IBRX 3
- Target Price
- OPRA $24.80
- IBRX $13.58
- AVG Volume (30 Days)
- OPRA 429.0K
- IBRX 6.0M
- Earning Date
- OPRA 02-27-2025
- IBRX 03-18-2025
- Dividend Yield
- OPRA 7.96%
- IBRX N/A
- EPS Growth
- OPRA 142.24
- IBRX N/A
- EPS
- OPRA 1.78
- IBRX N/A
- Revenue
- OPRA $447,818,000.00
- IBRX $7,332,000.00
- Revenue This Year
- OPRA $21.46
- IBRX $2,359.81
- Revenue Next Year
- OPRA $15.79
- IBRX $808.10
- P/E Ratio
- OPRA $11.46
- IBRX N/A
- Revenue Growth
- OPRA 17.82
- IBRX 1218.71
- 52 Week Low
- OPRA $10.11
- IBRX $2.28
- 52 Week High
- OPRA $22.50
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- OPRA 48.32
- IBRX 52.26
- Support Level
- OPRA $20.67
- IBRX $3.35
- Resistance Level
- OPRA $22.50
- IBRX $4.27
- Average True Range (ATR)
- OPRA 0.94
- IBRX 0.31
- MACD
- OPRA 0.00
- IBRX 0.04
- Stochastic Oscillator
- OPRA 46.90
- IBRX 29.17
About OPRA Opera Limited
Opera Ltd is a world-wide internet brand with a large, engaged and growing base. It offers users products and services that include a variety of PC and mobile browsers, Opera Gaming portals and development tools, Opera News content recommendation products, and a number of e-commerce products and services. Its features include tabbed browsing, data savings, PC/mobile sync, and numerous features focused on privacy and security, including ad blocking and a built-in VPN. Its browser products include Opera Mini, Opera Browser for Android and iOS, Opera for Computers, Opera GX and Opera GX Mobile, separate browsers tailored for gamers. The newest addition of browsers is the beta release of a Web3-centric browser for PC and mobile which is tailored for crypto enthusiasts.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.